AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 231 min read$AMPH

PETERS WILLIAM J sold $103K of AMPH

PETERS WILLIAM J (CFO, EVP & TREASURER) sold 4,139 shares of Amphastar Pharmaceuticals, Inc. (AMPH) at $25.00 ($0.10M total) on 2026-09-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · PETERS WILLIAM J
Published Sep 23, 2026, 10:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 23, 2026, 10:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$AMPH
Neutral
high confidence
Mentioned
$AMPH
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AMPHNeutralLow
01

Why it matters

The disclosed sale is modest and pre‑arranged, offering limited trading insight.

02

Market read

Minor insider sell; unlikely to move the stock materially.

03

What to watch

Potential upcoming FDA decisions or pipeline news not reflected in this filing.

Relevance 3/10Novelty 4/10Timing: post‑filing

Background

Form 4 filings disclose insider trades; CFOs often use 10b5‑1 plans to sell shares systematically.

Company-level read

Ticker impact

$AMPHNeutralHigh confidence
Context

CFO sold 4,139 shares for $103,475 via a 10b5-1 plan, reducing his stake to 168,707 shares.

Expected impact

Limited short-term impact; price likely unchanged.

Evidence & confidence

Sale amount is small relative to market cap and follows a pre‑arranged plan, reducing actionable significance.

Market effects

Sector

No broader sector impact; typical insider transaction.

Regional

None

Global

None

Counterpoint

What could challenge this read

If CFO holds significant insider knowledge, even a small sale could hint at upcoming downside.

Key entities

  • Company
    Amphastar Pharmaceuticals, Inc.

    Biopharma company developing inhaled therapies.

  • Person
    William J. Peters

    Chief Financial Officer of Amphastar.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AMPH insider trading history →

Related articles

AUG 21
$BMYMedAI 8/10

Pharmaceuticals Stocks Q2 Highlights: Ocular Therapeutix (NASDAQ:OCUL)

Bristol-Myers Squibb (BMY) reported Q2 revenues of $12.97B, up 5.7% YoY, beating estimates. Zoetis (ZTS) reported flat revenues of $2.47B, missing estimates. Amphastar (AMPH) reported $183.9M in revenues, up 5.4% YoY, beating estimates. Eli Lilly (LLY) reported $22.97B in revenues, up 47.7% YoY, beating estimates. Market sentiment has shifted from AI to geopolitics.

finance.yahoo.com3 min
AUG 14
$AMPHMedAI 8/10

Amphastar (AMPH) Q2 2026 Earnings Call Transcript

Amphastar (AMPH) reported Q2 2026 net revenues of $183.9 million, up 5% from $174.4 million, and gross margin of 50.8% versus 49.6%. GAAP net income was $30.3 million ($0.67/share). Adjusted non-GAAP net income was $40.8 million ($0.91/share). IMS remediation tied to an FDA warning letter is expected to add $2 million to $3 million per quarter, while full-year sales growth guidance remains mid-single digit to high single digit.

fool.com6 min
AUG 6
$AMPHMedAI 8/10

Amphastar Pharmaceuticals (NASDAQ:AMPH) Posts Better

Amphastar Pharmaceuticals (NASDAQ:AMPH) reported Q2 2026 results with revenue up 5.4% year on year to $183.9 million, exceeding Wall Street estimates by 2%, according to the company. Non-GAAP adjusted EPS was $0.91, up from $0.85, and 48.3% above consensus. The stock rose 4.5% to $20.70 after the release.

financialcontent.com4 min
AUG 6
$AMPHMed

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026

Amphastar Pharmaceuticals, Inc. (AMPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 ​ Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026 ​ - Net revenues of $183.9 million for the three months ended June 30, 2026 ​ - GAAP net income of $30.3 million, or $0.67 per share, for the second quarter ​ - Adjusted no

SEC EDGAR 8-K7 min
JUL 9
$AMPHMedAI 8/10

A New Over-the-Counter Naloxone Nasal Spray Is Now Available at Pharmacies

The FDA approved Rextovy, a 4 mg naloxone hydrochloride nasal spray by Amphastar Pharmaceuticals, for over-the-counter sale on June 16, 2026. It joins Narcan (Emergent BioSolutions) and RiVive (Harm Reduction Therapeutics) as OTC naloxone options. The article cites overdose-death figures and says expanded access may affect retail pricing and availability.

medicaldaily.com5 min
JUN 10
$AMPHMed

Amphastar Pharmaceuticals Pivots to Proprietary Drugs, Biosimilars for Growth

Amphastar Pharmaceuticals said it is leaning more on proprietary drugs and biosimilars to drive growth, while keeping BAQSIMI and Primatene MIST as key branded products. In Phase 1, AMP-101 (intranasal epinephrine) and other early programs include AMP-105/109 oncology and AMP-107 for wet AMD. The company forecasts BAQSIMI peak sales of $250–$275M and peak incremental adjusted EPS of $2–$2.50, and Primatene MIST sales of $109M last year with high-single-digit growth. Amphastar reported $285M cash

finance.yahoo.com7 min